Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group

BACKGROUND: Patients with resistant primary focal segmental glomerulosclerosis (FSGS) are at high risk of progression to chronic kidney disease stage V. Antifibrotic agents may slow or halt this process. We present outcomes of follow-up after a Phase I trial of adalimumab and rosiglitazone, antifibr...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Peyser, Alexandra, MacHardy, Nathaniel, Tarapore, Freya, MacHardy, Jacqueline, Powell, Leslie, Gipson, Debbie S, Savin, Virginia, Pan, Cynthia, Kump, Theresa, Vento, Suzanne, Trachtman, Howard
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2010
Ämnen:
Research article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2823728/
https://ncbi.nlm.nih.gov/pubmed/20113498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2369-11-2
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk